factors associated with treatment response to cd19 car t-cell therapy in b-all
Published 2 years ago • 57 plays • Length 3:42Download video MP4
Download video MP3
Similar videos
-
2:20
risk factors for success or failure of cd19-directed car-t therapy in children with b-all
-
0:45
bispecific car t-cell therapy: combining anti-cd19 and cd22 car t-cells
-
2:26
clinical data for cd19-directed car t-cell products in all
-
1:16
the efficacy of car t-cell therapy in richter's transformation
-
1:21
anti-cd22 car t-cell therapy for all: trial update, utility for salvage and cd19 status
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:36
the use of outpatient cilta-cel in the treatment of multiple myeloma
-
3:03
the impact of salvage and bridging therapy on car t-cell therapy outcomes in b-all: an itt analysis
-
3:31
a summary of the prognostic factors that can influence the outcomes of anti-cd19 car-t in r/r dlbcl
-
1:32
factors contributing to the pathogenesis of icaht
-
2:26
feasibility of sequential treatment with cd19-targeted agents in patients with lbcl
-
3:06
repeat infusions of cd19 car-t
-
3:01
mechanisms of antigen escape following cd19-directed car-t therapy
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
10:22
cd19 car-t in lymphoma patients in the uk
-
3:07
the role of bridging and timing in car-t
-
1:40
overcoming antigen escape following cd19-directed car-t therapy
-
4:12
opportunities to improve car-t outcomes